These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 526925)

  • 21. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
    Vadlamudi S; Goldin A
    Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
    [No Abstract]   [Full Text] [Related]  

  • 22. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
    Kataoka T; Kobayashi T
    Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antileukemic activity of liposome forms of cytosine arabinoside and cyclocytidine].
    Reshchikov VP; Afonin NI; Ermakov LN; Fertukova NM; Oksinoĭd OE
    Gematol Transfuziol; 1984; 29(5):49-51. PubMed ID: 6203808
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 26. Inability of liposome encapsulated 1-beta-D-arabinofuranosylcytosine nucleotides to overcome drug resistance in L1210 cells.
    Rustum YM; Mayhew E; Szoka F; Campbell J
    Eur J Cancer Clin Oncol; 1981 Jul; 17(7):809-17. PubMed ID: 7199474
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of methotrexate and cytosine arabinoside on polyamine metabolism in a mouse L1210 leukemia.
    Russell DH
    Cancer Res; 1972 Nov; 32(11):2459-62. PubMed ID: 5082594
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
    Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A
    Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia.
    Mayer LD; Nayar R; Thies RL; Boman NL; Cullis PR; Bally MB
    Cancer Chemother Pharmacol; 1993; 33(1):17-24. PubMed ID: 8269584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
    Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
    Ninomiya K; Sekido S; Araki T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 34. Enhancement of 1-beta-D-arabinofuranosylcytosine accumulation within L1210 cells and increased cytotoxicity following thymidine exposure.
    Grant S; Lehman C; Cadman E
    Cancer Res; 1980 May; 40(5):1525-31. PubMed ID: 7370990
    [No Abstract]   [Full Text] [Related]  

  • 35. Liposomal potentiation of the antitumor activity of alkylating drugs.
    Rutman RJ; Ritter CA; Avadhani NG; Hansel J
    Cancer Treat Rep; 1976 May; 60(5):617-8. PubMed ID: 991151
    [No Abstract]   [Full Text] [Related]  

  • 36. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC; Goldberg D; Schein PS
    Biochem Pharmacol; 1973 Jan; 22(2):277-80. PubMed ID: 4763256
    [No Abstract]   [Full Text] [Related]  

  • 38. [Ultrastructure of the myelin-like particles in the liver of mice administered liposomes with various levels of cholesterol and phosphatidylcholine].
    Chebanov SM; Torchilin VP; Berdichevskiĭ VR; Loginov AS; Smirnov VN
    Biull Eksp Biol Med; 1983 Apr; 95(4):110-3. PubMed ID: 6831003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract]   [Full Text] [Related]  

  • 40. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.